Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sstr2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Sstr2. Displaying page 1 of 1.
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000983-17 Sponsor Protocol Number: MN3 Start Date*: 2008-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Diagnostic procedure with 68Ga-labelled somatostatin analogues in tumours presumably expressing SSTR2 and/or 5 receptors, to be evaluated for treatment with the same analogues labelled with 90Y o 1...
    Medical condition: Valutation of expression of receptors SSTR2 and/or 5 in neoplastic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022893 Investigations, imaging and histopathology procedures NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004727-31 Sponsor Protocol Number: IRST100.26 Start Date*: 2016-03-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: RANDOMIZED PHASE II TRIAL IN SSTr2 POSITIVE TUMORS TO OPTIMIZE THE INTERVAL BETWEEN CYCLES OF PRRT WITH 177LU DOTATATE (LUTHREE)
    Medical condition: SSTr2 POSITIVE TUMORS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001468-12 Sponsor Protocol Number: PEN-221-001 Start Date*: 2017-01-16
    Sponsor Name:Tarveda Therapeutics, Inc.
    Full Title: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing ad...
    Medical condition: Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000028-33 Sponsor Protocol Number: D-FR-01070-003 Start Date*: 2018-07-17
    Sponsor Name:Ipsen Pharma
    Full Title: A non-randomised, phase II study to evaluate the optimal uptake time of 68Ga-OPS202 as a sstr2 positive PET imaging agent in subjects with newly diagnosed breast cancer. (Sub-study of Master Protoc...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002526-23 Sponsor Protocol Number: 68GaPET-Meningioma-2013 Start Date*: 2014-02-12
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
    Medical condition: Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004626-34 Sponsor Protocol Number: MetNET2 Start Date*: 2016-03-08
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, pr...
    Medical condition: Patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000897-65 Sponsor Protocol Number: MN2 Start Date*: 2006-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.
    Medical condition: Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002960-42 Sponsor Protocol Number: Yttrium-90-02 Start Date*: 2017-11-15
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90...
    Medical condition: Patients with Somatostatin receptors Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002194-22 Sponsor Protocol Number: A-97-52030-270 Start Date*: 2014-01-14
    Sponsor Name:Ipsen Limited
    Full Title: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progr...
    Medical condition: Symptoms of Neuro Endocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004928-39 Sponsor Protocol Number: D-FR-01070-002 Start Date*: 2017-11-23
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumo...
    Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005579-10 Sponsor Protocol Number: A-93-52030-325 Start Date*: 2016-02-26
    Sponsor Name:IPSEN S.P.A.
    Full Title: EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS
    Medical condition: progressive well differentiated thoracic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007282 Carcinoid tumour pulmonary PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037342 Pulmonary carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068115 Metastatic carcinoid tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004413-15 Sponsor Protocol Number: CSOM230B2209 Start Date*: 2006-06-07
    Sponsor Name:Cedars Sinai Medical Center
    Full Title: Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomas
    Medical condition: non-functioning pitiutary adenomes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035079 Pituitary adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005607-24 Sponsor Protocol Number: 8-79-52030-326 Start Date*: 2015-11-30
    Sponsor Name:Ipsen Innovation
    Full Title: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having ...
    Medical condition: well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004506-10 Sponsor Protocol Number: LOLATrial Start Date*: 2020-03-13
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
    Medical condition: gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000086-14 Sponsor Protocol Number: IRST100.60 Start Date*: 2023-04-14
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
    Medical condition: Patients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 14:34:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA